Lifeboat Foundation

This month, K.L. became one of the first patients to receive a new experimental gene therapy for children with a severe form of inherited vision loss. The treatment, currently not yet named, targets young men who are susceptible to a particularly vicious genetic disorder that gradually destroys the light-sensing portion of their eyes.

Within a month following a single injection, “my vision was beginning to return in the treated eye. The sharpness and depth of colors I was slowly beginning to see were so clear and attractive,” said K.L.

The trial, a first-in-human case for X-linked Retinitis Pigmentosa (RP), was led by Dr. Robert MacLaren at the University of Oxford but spanned multiple centers including the Bascom Palmer Eye Institute in Miami, which previously championed Luxterna, the first FDA-approved gene therapy for a type of inherited blindness. The results are some of the first targeting a particularly difficult gene prone to mutation in humans. Amazingly, despite some inflammation in early stages, the therapy provided massive improvements in eyesight as early as two weeks following treatment.

If you’d like to share this article you can do so from here: https://m.facebook.com/story.php?story_fbid=539550403339975&id=383136302314720

Michigan-native doctor was honored in his hometown for making national headlines after helping a paralyzed man walk again.

Catalogue of 68 billion tunes contains ‘every melody that’s ever existed and ever can exist’

In a recent study, scientists at Baycrest’s Rotman Research Institute (RRI) found that research participants moved their eyes to determine whether they had seen an image before, and that their eye movement patterns could predict mistakes in memory. They obtained these results using an innovative new eye tracking technique they developed.

“Our findings indicate that eye movements play a functional role in memory retrieval,” says Dr. Jennifer Ryan, senior scientist at the RRI and Canada Research Chair in Cognitive Neuroscience of Memory. “They can tell us a lot about someone’s memory.”

This study builds on previous Baycrest research examining the link between eye movements and memory, including the role of our eye movements in memorization and the weakening connection between our eye movements and our brain activity as we age.

A lithium-ion battery that is safe, has high power and can last for 1 million miles has been developed by a team in Penn State’s Battery and Energy Storage Technology (BEST) Center.

Electric vehicle batteries typically require a tradeoff between safety and energy density. If the battery has high energy and power density, which is required for uphill driving or merging on the freeway, then there is a chance the battery can catch fire or explode in the wrong conditions. But materials that have low energy/power density, and therefore high safety, tend to have poor performance. There is no material that satisfies both. For that reason, battery engineers opt for performance over safety.

“In this work we decided we were going to take a totally different approach,” said Chao-Yang Wang, professor of mechanical, chemical and materials science and engineering, and William E. Diefenderfer Chair in Mechanical Engineering, Penn State. “We divided our strategy into two steps. First we wanted to build a highly stable battery with highly stable materials.”

By allowing video calls

Approach could make manipulating a prosthesis more natural, precise, and reliable.

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) report new data that support the hypothesis that remdesivir, a drug with broad antiviral activity, may be a promising treatment against Middle East respiratory syndrome coronavirus (MERS-CoV).

In the team’s experiments, remdesivir reduced the severity of disease, virus replication, and damage to the lungs when administered to infected monkeys. The authors suggest that it be considered for implementation in clinical trials and that it may also have utility for other, related coronaviruses, such as SARS-CoV-2 (previously known as 2019-nCoV).

The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with MERS-CoV. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.

Is it so outlandish to believe that countries in the future might resort to military force to prevent other countries from altering the shared genetic code of humanity? Many countries have been invaded for far less.

The genetics revolution that will transform our health care, the way we make babies, the nature of the babies we make, and ultimately our evolutionary trajectory as a species has already begun. Just like parents in many places will need to make tough choices about whether, if at all, to genetically engineer their children, states will be forced to make monumental collective decisions on these issues with potentially fateful consequences.

Continue reading “The designer baby debate could start a war” »